Allergan (AGN) Reaches New 1-Year Low at $158.21
Shares of Allergan plc (NYSE:AGN) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $158.21 and last traded at $158.74, with a volume of 2626172 shares trading hands. The stock had previously closed at $164.20.
A number of analysts recently issued reports on AGN shares. JPMorgan Chase & Co. set a $275.00 price target on Allergan and gave the company a “buy” rating in a report on Sunday, October 22nd. Cowen set a $280.00 price target on Allergan and gave the company a “buy” rating in a report on Friday, October 20th. Sanford C. Bernstein set a $252.00 price target on Allergan and gave the company a “buy” rating in a report on Wednesday, October 18th. Deutsche Bank set a $251.00 price target on Allergan and gave the company a “buy” rating in a report on Tuesday, October 17th. Finally, UBS Group set a $255.00 price target on Allergan and gave the company a “buy” rating in a report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $227.23.
The firm has a market capitalization of $54,130.00, a P/E ratio of -13.58, a P/E/G ratio of 1.18 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.08.
The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.77%. Allergan’s dividend payout ratio is presently -23.35%.
In other Allergan news, Director Christopher J. Coughlin purchased 10,000 shares of Allergan stock in a transaction dated Tuesday, December 5th. The shares were acquired at an average cost of $163.30 per share, with a total value of $1,633,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider William Meury sold 11,807 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Cable Hill Partners LLC increased its position in shares of Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. increased its position in shares of Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares in the last quarter. Phocas Financial Corp. acquired a new position in shares of Allergan during the second quarter worth $150,000. BB&T Investment Services Inc. increased its position in shares of Allergan by 1,308.2% during the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after purchasing an additional 641 shares in the last quarter. Finally, WFG Advisors LP increased its position in shares of Allergan by 20.9% during the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after purchasing an additional 137 shares in the last quarter. 80.23% of the stock is currently owned by institutional investors and hedge funds.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.